We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : TLT.v -- Ignore unavailable to you. Want to Upgrade?

To: Underexposed who wrote (1414)11/9/2019 3:07:46 AM
From: 3bar  Respond to of 1641
This is correct " I don't think this affects the Phase II study at all as a different laser is being used. "

2 separate systems the recall has no effect on the Phase 11 trial . This was verified by a phone call .

To: Underexposed who wrote (1414)11/11/2019 8:00:26 AM
From: ogi  Read Replies (2) | Respond to of 1641
Yes, I understand the recall is independent of the trial. But as you say a Cluster F and one that in my view must be closely related to the departure of the device division CEO. Ie is all well at head office? It is simply another incident that does not inspire confidence in a management that has already been sanctioned by the OSC. I think the medical division science is so complex, requires very specific skill sets and has such incredibly good scientists on board it is harder for bad management to interfere.

Tlt has stated Europe has been dropped in favour of just Canada and U.S..

The sooner the U.S. gets underway the sooner TLT has access to 10x the possible trial participants and the more TLT becomes attractive to U.S. investors.

I too continue to be encouraged by Phase 1 trial results and can only imagine phase 2 trial will have minor procedural improvements that will benefit the process and we shall see if the double dose also improves results.